Our Opinion

Immune Design Corp. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical products and clinical research.

Supporting Evidence:

The company stated in the following report that they conduct pre-clinical trials of their drugs on animals.

“In addition, G100 had an impact on the tumor microenvironment, changing it from a non-inflammatory state, or “cold” tumor, to an inflamed state, or “hot” tumor. Specifically, as shown in the image below, responding animals remained tumor-free at least three months post G100 treatment and, without administration of additional G100, were resistant to secondary challenge with the same tumor type.” (Page 5) Read the following document

Company Description

Immune Design Corp. is a clinical-stage immunotherapy company, which focuses on cancer with next-generation in vivo approaches designed to enable the body’s immune system to fight disease. It includes products candidates from discovery platforms, IMDZVe or ZVex, and GLAAS. The company was founded by Steven G. Reed and David Baltimore on February 20, 2008 and is headquartered in Seattle, WA. [Source: MarketWatch]

Company Website: http://www.immunedesign.com